Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Gilead Sciences, Inc. (GILD), Merck & Co., Inc. (MRK), and Oral Hepatitis C Cure on Its Way

Page 1 of 2

Gilead Sciences, Inc. (NASDAQ:GILD) moved one step closer to an all-oral cure for hepatitis C on Monday when the company submitted its application to the Food and Drug Administration to market sofosbuvir for the viral infection.

Gilead Sciences, Inc. (NASDAQ:GILD)The current regimen for patients with hepatitis C involves taking one of two oral drugs — either Merck & Co., Inc. (NYSE:MRK)‘s Victrelis or Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)‘ Incivek — plus an oral generic called ribavirin and a branded a pegylated interferon drug, either Merck & Co., Inc. (NYSE:MRK)’s PegIntron or Roche‘s Pegasys. Pegylated interferons have to be injected, which patients generally don’t like, and more importantly, they also cause uncomfortable side effects, including flu-like symptoms. Considering they have to be taken for six months or more, it’s understandable why patients don’t like them.

Short-term subdued
Sofosbuvir passed four phase 3 trials. It seems very likely that the FDA will approve the drug in eight to 12 months depending on whether the drug is given a priority review.

But for most hepatitis C patients, sofosbuvir isn’t a cure-all by itself. When the drug is combined with ribavirin, it does a pretty good job at curing patients with genotype 2 and 3, but the most common genotype in the U.S. is genotype 1. Patients with genotype 1, along with genotype 4, 5, and 6, will still have to take PegIntron or Pegasys and ribavirin if sofosbuvir is approved.

While some patients will do just that, many will wait. Hepatitis C is a slow -cting disease. Eventually the virus starts to damage the liver, including potentially causing liver cancer, but it takes a long time to get that far. Most patients can wait for a better treatment.

They’re already doing that. Sales of Incivek and Victrelis peaked shortly not long after their launches as patients wait for better treatments. Sales of sofosbuvir will likely follow the same path. At least initially.

Long-term lucrative
Gilead Sciences, Inc. (NASDAQ:GILD) is testing sofosbuvir in combination with another oral medication, GS-5885, with and without ribavirin in genotype 1 patients. If the phase 3 trials turn out positive, the additional data could be added to the label after it’s approved. Doctors can prescribe it off-label before that, but they’d have to wait for GS-5885 — or a fixed-dose combination pill that contained both medications — to be approved.

How big of a blockbuster sofosbuvir becomes depends on how good the data is compared to other all-oral cocktails being developed by AbbVie Inc (NYSE:ABBV), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Johnson & Johnson (NYSE:JNJ), and many others. The cure rates will be important, but as they exceed 90%, safety and the amount of time patients have to take the drug will become more important.

Page 1 of 2
Loading Comments...